Search Result

Results for "

lipoprotein receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	LDLR (2) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (7) Autophagy (5) Biochemical Assay Reagents (1) Cytochrome P450 (2) Endogenous Metabolite (1) Fatty Acid Synthase (FASN) (1) FXR (3) HCV (1) HMG-CoA Reductase (HMGCR) (5) Isotope-Labeled Compounds (1) LXR (1) MicroRNA (1) Mitophagy (5) Phosphatase (1) Phospholipase (1) PPAR (1) RAR/RXR (1) ROR (2) SARS-CoV (1) Ser/Thr Protease (5) Thyroid Hormone Receptor (1) Toll-like Receptor (TLR) (1) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (9) Cardiovascular Disease (8) Endocrinology (1) Infection (1) Inflammation/Immunology (3) Metabolic Disease (14) Neurological Disease (5)

By Targets:

LDLR (2)

Antibody-Drug Conjugates (ADCs) (1)

Apoptosis (7)

Autophagy (5)

Biochemical Assay Reagents (1)

Cytochrome P450 (2)

Endogenous Metabolite (1)

Fatty Acid Synthase (FASN) (1)

FXR (3)

HCV (1)

HMG-CoA Reductase (HMGCR) (5)

Isotope-Labeled Compounds (1)

LXR (1)

MicroRNA (1)

Mitophagy (5)

Phosphatase (1)

Phospholipase (1)

PPAR (1)

RAR/RXR (1)

ROR (2)

SARS-CoV (1)

Ser/Thr Protease (5)

Thyroid Hormone Receptor (1)

Toll-like Receptor (TLR) (1)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (9)

Cardiovascular Disease (8)

Endocrinology (1)

Infection (1)

Inflammation/Immunology (3)

Metabolic Disease (14)

Neurological Disease (5)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: LDLR LOX-1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N2339

Cholesteryl behenate 1 Publications Verification Cholesteryl docosanoate; Cholesterol behenate	Endogenous Metabolite	Metabolic Disease
Cholesteryl behenate is a cholesterol ester associated with the neutral core of low density lipoprotein Receptor-LDL complexes are taken up by lysosomes and hydrolyzed to release cholesterol from the esters.

HY-148758

PCSK9-IN-13	Ser/Thr Protease	Metabolic Disease
PCSK9-IN-13(compound 3f) is a potent PCSK9 inhibitor, which can antagonize low-density lipoprotein (LDL) receptor binding by binding to PCSK9, with an IC₅₀ of 537 nM .

HY-102004

Rilapladib 1 Publications Verification SB 659032	Phospholipase	Neurological Disease Inflammation/Immunology
Rilapladib (SB 659032) is a selective Lp-PLA₂ (lipoprotein-associated phospholipase A₂) inhibitor with an IC₅₀ of 230 pM . Rilapladib (SB 659032) is also a PAFR (Platelet Activating Factor Receptor) antagonist .

HY-147279

Milpocitide

LDLR Others

Milpocitide is a low-density lipoprotein receptor (human LDL receptor, LDLR), (293-333)-peptide fragment (EGF-like domain 1) .

Milpocitide	LDLR	Others
Milpocitide is a low-density lipoprotein receptor (human LDL receptor, LDLR), (293-333)-peptide fragment (EGF-like domain 1) .

HY-W510159

5-O-Methylembelin	Ser/Thr Protease	Cardiovascular Disease
5-O-Methylembelin is a natural isocoumarin that inhibits PCSK9, *inducible degrader of the low-density lipoprotein* receptor (IDLR), and sterol regulatory element binding protein 2 (SREBP2)** mRNA expression .

HY-N1881

4',5-Dihydroxyflavone
4',5-Dihydroxyflavone is a soybean LOX-1 and yeast α-Glucosidase inhibitor, with an K_i of 102.6 μM for soybean LOX-1 and an IC₅₀ of 66 μM for yeast α-glucosidase. LOX-1 isshort for Lectin-like oxidized low-density lipoprotein receptor-1.

HY-101529

Imanixil HOE-402(free base)	LDLR	Cardiovascular Disease
Imanixil (HOE-402 free base) is an inducer of the LDL receptor (LDLR). Imanixil (HOE-402 free base) is also a potent cholesterol-lowering compound, which inhibits very low density-lipoprotein (VLDL) production, and consequently attenuates atherosclerosis development .

HY-10473

Eprotirome KB2115	Thyroid Hormone Receptor	Metabolic Disease Endocrinology
Eprotirome (KB2115) is a liver-selective *thyroid hormone receptor* (TR) agonist. KB2115 has modestly higher affinity for TRβ than for TRα*. Eprotirome reduces low-density lipoprotein* (LDL) cholesterol concentrations. Eprotirome can be used for dyslipidemias and obesity research .

HY-130245

PCSK9 degrader 1	Ser/Thr Protease	Metabolic Disease
PCSK9 degrader 1 (Compound 16) is a small molecule ligand for proprotein convertase substilisin-like/kexin type 9 (PCSK9) and shows high affinity to PCSK9 with a K_i of 107 nM. PCSK9 degrader 1 can involve in a protein-protein interaction with the low-density lipoprotein (LDL) receptor .

HY-116767

BLT-1 3 Publications Verification Block lipid transport-1	HCV	Metabolic Disease Inflammation/Immunology
BLT-1, a thiosemicarbazone copper chelator, is a selective *scavenger receptor* B, type 1 (SR-BI)** inhibitor. BLT-1 inhibits the transfer of lipids between high-density lipoproteins (HDL) and cells mediated by SR-BI. BLT-1 is a potent HCV entry inhibitor .

HY-B0144AS1

Pitavastatin-d5 sodium NK-104-d₅ sodium	Apoptosis HMG-CoA Reductase (HMGCR) Mitophagy Autophagy	Metabolic Disease Cancer
Pitavastatin-d₅ (sodium) is the deuterium labeled Pitavastatin sodium. Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity.

HY-P99822

Recaticimab SHR-1209	Ser/Thr Protease	Metabolic Disease
Recaticimab (SHR-1209) is a humanized monoclonal antibody that inhibits PCSK9. Receticimab mediates the degradation of PCSK9 by binding to PCSK9, increasing the level of low-density lipoprotein (LDL) receptors on the surface of hepatocytes, reducing the level of LDL in plasma, and achieving the goal of lowering blood lipids. Recaticimab has potential application in hypercholesterolemia .

HY-10626

T0901317 Maximum Cited Publications 22 Publications Verification	LXR FXR ROR Apoptosis	Cardiovascular Disease Metabolic Disease Cancer
T0901317 is an orally active and highly selective LXR agonist with an EC₅₀ of 20 nM for LXRα . T0901317 activates FXR with an EC₅₀ of 5 μM . T0901317 is RORα and RORγ dual inverse agonist with K_i values of 132 nM and 51 nM, respectively . T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice .

HY-122816

HLY78 5+ Cited Publications	Wnt β-catenin Apoptosis	Cardiovascular Disease Neurological Disease Cancer
HLY78, a Lycorine (HY-N0288) derivative, is a potent activator of the Wnt/β-catenin signaling pathway. HLY78 targets the DIX domain of Axin and promotes the Axin-LRP6 (lipoprotein receptor-related protein 6) association, thus promoting LRP6 phosphorylation and Wnt signal transduction. HLY78 can be used for subarachnoid hemorrhage (SAH) research .

HY-P9928A

Alirocumab (anti-PCSK9) 1 Publications Verification REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)	Ser/Thr Protease	Cardiovascular Disease
Alirocumab (anti-PCSK9) is a human monoclonal antibody inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9). Alirocumab specifically binds PCSK9, a down regulator of liver low-density lipoprotein (LDL)-receptors, thereby increasing the ability of the liver to bind LDL-cholesterol (LDL-C) and reducing levels of LDL-C in blood. Alirocumab can be used for the research of hypercholesterolemia .

HY-P4073

ANG1005 GRN1005; Paclitaxel trevatide	Antibody-Drug Conjugates (ADCs)	Cancer
ANG1005 (Paclitaxel trevatide) is a brain-penetrating peptide-drug conjugate. ANG1005, a taxane derivative, consists of three paclitaxel (HY-B0015) molecules covalently linked to Angiopep-2, designed to cross the blood-brain and blood-cerebrospinal barriers and to penetrate malignant cells via low density lipoprotein receptor-related protein (LRP1) transport system .

HY-B0144A

Pitavastatin 4 Publications Verification NK-104	HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC₅₀ of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .

HY-B0144B

Pitavastatin sodium NK-104 sodium	HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Pitavastatin (NK-104) sodium is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin sodium inhibits cholesterol synthesis from acetic acid with an IC₅₀ of 5.8 nM in HepG2 cells. Pitavastatin sodium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin sodium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .

HY-108471

CU-CPT22 5+ Cited Publications	Toll-like Receptor (TLR)	Cancer
CU-CPT22 is a potent protein complex of *toll-like receptor* 1 and 2 (TLR1/2)** inhibitor, and competes with the synthetic triacylated lipoprotein (Pam₃CSK₄) binding to TLR1/2 with a K_i of 0.41 µM. CU-CPT22 blocks Pam₃CSK₄-induced TLR1/2 activation with an IC₅₀ of 0.58 µM .

HY-144120

αGalCer-RBD	SARS-CoV	Infection
αGalCer-RBD is a self-adjuvanting lipoprotein conjugate. αGalCer-RBD induces potent immunity against SARS-CoV-2 and its variants of concern. αGalCer-RBD conjugate induces RBD-specific, cytokine-producing T cell development. αGalCer-RBD has great potential to be an effective COVID-19 vaccine candidate. α-Galactosylceramide (αGalCer) is a potent invariant natural killer T cell (iNKT) agonist . RBD: receptor-binding domain

HY-B0144S

Pitavastatin-d4 hemicalcium NK-104-d₄ hemicalcium; Pitavastatin-d₄ hemicalcium	Isotope-Labeled Compounds HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis	Metabolic Disease Cancer
Pitavastatin-d₄ (hemicalcium) is deuterium labeled Pitavastatin (Calcium). Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity[1][2][3].

HY-B0144

Pitavastatin Calcium 4 Publications Verification NK-104 hemicalcium; Pitavastatin hemicalcium	HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC₅₀ of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin Calcium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .

HY-N0686

Pseudoprotodioscin 1 Publications Verification	Fatty Acid Synthase (FASN) MicroRNA	Metabolic Disease
Pseudoprotodioscin, a furostanoside, inhibits SREBP1/2 and microRNA 33a/b levels and reduces the gene expression regarding the synthesis of cholesterol and triglycerides .

HY-163436

F44-A13	FXR Cytochrome P450 RAR/RXR PPAR ROR	Metabolic Disease
F44-A13 is an orally active and highly selective farnesoid X receptor (FXR) antagonist with an IC₅₀ value of 1.1 μM. F44-A13 can optimize cholesterol metabolism and reduce its activity by inducing CYP7A1 expression. F44-A13 reduces levels of cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C) in mouse models. F44-A13 can be used in the study of metabolic diseases associated with lipid disorders .

HY-126726

KOdiA-PC	Biochemical Assay Reagents	Others
Oxidized low-density lipoprotein (oxLDL) particles contain low molecular weight species that are cytotoxic and proatherogenic. Many of these species were recently isolated and purified from oxLDL and identified as phosphatidylcholine species containing fragmented oxidized short-chain fatty acid residues at the sn-2 position. 1-(Palmitoyl)-2-(5-keto-6-octene-dioyl)phosphatidylcholine or KOdiA-PC is one of the most potent CD36 ligands of the oxLDL species. KOdiA-PC confers CD36 scavenger receptor binding affinity to LDL at a frequency of only 2 to 3 KOdiA-PC molecules/LDL particle and may be one of the more important structural determinants of oxLDL.

HY-134988

EDP-305	FXR Phosphatase Cytochrome P450	Inflammation/Immunology
EDP-305 is an orally active, potent and selective farnesoid X receptor (FXR) agonist, with EC₅₀ values of 34 nM (chimeric FXR in CHO cells) and 8 nM (full-length FXR in HEK cells). EDP-305 shows a potent and consistent antifibrotic effect. EDP-305 can be used for primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH) research .

KOdiA-PC	Biochemical Assay Reagents
Oxidized low-density lipoprotein (oxLDL) particles contain low molecular weight species that are cytotoxic and proatherogenic. Many of these species were recently isolated and purified from oxLDL and identified as phosphatidylcholine species containing fragmented oxidized short-chain fatty acid residues at the sn-2 position. 1-(Palmitoyl)-2-(5-keto-6-octene-dioyl)phosphatidylcholine or KOdiA-PC is one of the most potent CD36 ligands of the oxLDL species. KOdiA-PC confers CD36 scavenger receptor binding affinity to LDL at a frequency of only 2 to 3 KOdiA-PC molecules/LDL particle and may be one of the more important structural determinants of oxLDL.

ANG1005 GRN1005; Paclitaxel trevatide	Antibody-Drug Conjugates (ADCs)	Cancer
ANG1005 (Paclitaxel trevatide) is a brain-penetrating peptide-drug conjugate. ANG1005, a taxane derivative, consists of three paclitaxel (HY-B0015) molecules covalently linked to Angiopep-2, designed to cross the blood-brain and blood-cerebrospinal barriers and to penetrate malignant cells via low density lipoprotein receptor-related protein (LRP1) transport system .

Recaticimab SHR-1209	Ser/Thr Protease	Metabolic Disease
Recaticimab (SHR-1209) is a humanized monoclonal antibody that inhibits PCSK9. Receticimab mediates the degradation of PCSK9 by binding to PCSK9, increasing the level of low-density lipoprotein (LDL) receptors on the surface of hepatocytes, reducing the level of LDL in plasma, and achieving the goal of lowering blood lipids. Recaticimab has potential application in hypercholesterolemia .

Alirocumab (anti-PCSK9) 1 Publications Verification REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)	Ser/Thr Protease	Cardiovascular Disease
Alirocumab (anti-PCSK9) is a human monoclonal antibody inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9). Alirocumab specifically binds PCSK9, a down regulator of liver low-density lipoprotein (LDL)-receptors, thereby increasing the ability of the liver to bind LDL-cholesterol (LDL-C) and reducing levels of LDL-C in blood. Alirocumab can be used for the research of hypercholesterolemia .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2339

Cholesteryl behenate 1 Publications Verification Cholesteryl docosanoate; Cholesterol behenate	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Cholesteryl behenate is a cholesterol ester associated with the neutral core of low density lipoprotein Receptor-LDL complexes are taken up by lysosomes and hydrolyzed to release cholesterol from the esters.

HY-N0686

Pseudoprotodioscin 1 Publications Verification	Structural Classification Natural Products Classification of Application Fields Dioscorea nipponica Makino Source classification Metabolic Disease Plants Disease Research Fields Dioscoreaceae	Fatty Acid Synthase (FASN) MicroRNA
Pseudoprotodioscin, a furostanoside, inhibits SREBP1/2 and microRNA 33a/b levels and reduces the gene expression regarding the synthesis of cholesterol and triglycerides .

HY-W510159

5-O-Methylembelin	Structural Classification Lysimachia vulgarisL. Source classification Coumarins Phenylpropanoids Plants Primulaceae	Ser/Thr Protease
5-O-Methylembelin is a natural isocoumarin that inhibits PCSK9, *inducible degrader of the low-density lipoprotein* receptor (IDLR), and sterol regulatory element binding protein 2 (SREBP2)** mRNA expression .

Species:	Human (10) Mouse (2) Rat (2) Cynomolgus (1)
Tag:	His (11) Avi (1) Fc (4)
Source:	HEK293 (15)

Cat. No.	Compare	Product Name	Species	Source

HY-P70235

	LDLR Protein, Human (HEK293, His) 1 Publications Verification rHuLow-density lipoprotein receptor/LDLR, His; Low-Density lipoprotein receptor; LDL receptor; LDLR	Human	HEK293
	LDLR Protein plays a pivotal role in cholesterol homeostasis, binding to LDL and mediating cellular uptake through endocytosis. Clustering into clathrin-coated pits is essential for internalization. In microbial infection, LDLR acts as a receptor for hepatitis C virus in hepatocytes, emphasizing its dual functionality in cholesterol metabolism and the cellular response to viral infections. LDLR Protein, Human (HEK293, His) is the recombinant human-derived LDLR protein, expressed by HEK293 , with C-6*His labeled tag. The total length of LDLR Protein, Human (HEK293, His) is 767 a.a., with molecular weight of 99-135 kDa.

HY-P73272

	LDLR Protein, Mouse (HEK293, His) Low-density lipoprotein receptor; LDLR; LDL receptor	Mouse	HEK293
	LDLR Protein crucially binds to LDL, transporting cholesterol through endocytosis. Clustering into clathrin-coated pits initiates internalization. Interactions with DAB2, LDLRAP1, ARRB1, SNX17, and immature PCSK9 contribute to its functional versatility. The NPXY motif interaction is impaired by tyrosine phosphorylation. LDLR Protein, Mouse (HEK293, His) is the recombinant mouse-derived LDLR protein, expressed by HEK293 , with C-His labeled tag. The total length of LDLR Protein, Mouse (HEK293, His) is 769 a.a., with molecular weight of ~98-130 kDa.

HY-P72392

	LDLR Protein, Human (Biotinylated, HEK293, Avi-His) Low-Density lipoprotein receptor; LDL receptor; LDLR	Human	HEK293
	LDLR Protein plays a pivotal role in cholesterol homeostasis, binding to LDL and mediating cellular uptake through endocytosis. Clustering into clathrin-coated pits is essential for internalization. In microbial infection, LDLR acts as a receptor for hepatitis C virus in hepatocytes, emphasizing its dual functionality in cholesterol metabolism and the cellular response to viral infections. LDLR Protein, Human (Biotinylated, HEK293, Avi-His) is the recombinant human-derived LDLR protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag. The total length of LDLR Protein, Human (Biotinylated, HEK293, Avi-His) is 767 a.a., with molecular weight of 95-140 kDa.

HY-P76125

	VLDLR Protein, Human (HEK293, His) Very low-density lipoprotein receptor; VLDL-R	Human	HEK293
	VLDLR protein, a versatile receptor, mediates energy metabolism by binding and transporting VLDL into cells. It interacts with Reelin/RELN, APOE-containing ligands, and clusterin/CLU. Inactive VLDLR forms oligomers with LRP8, but upon ligand binding, it rearranges to transmit the extracellular RELN signal via DAB1 phosphorylation, regulating neuron positioning. VLDLR also acts as a stop signal for migrating neurons and serves as a receptor for Semliki Forest virus during microbial infection. VLDLR Protein, Human (HEK293, His) is the recombinant human-derived VLDLR protein, expressed by HEK293, with C-His labeled tag. The total length of VLDLR Protein, Human (HEK293, His) is 770 a.a., with molecular weight (glycosylation form) of 110-130 kDa.

HY-P73838

	LDLR Protein, Mouse (Biotinylated, A23V, C27G, HEK293, His) Low-density lipoprotein receptor; LDLR; LDL receptor	Mouse	HEK293
	LDLR Protein crucially binds to LDL, transporting cholesterol through endocytosis. Clustering into clathrin-coated pits initiates internalization. Interactions with DAB2, LDLRAP1, ARRB1, SNX17, and immature PCSK9 contribute to its functional versatility. The NPXY motif interaction is impaired by tyrosine phosphorylation. LDLR Protein, Mouse (Biotinylated, A23V, C27G, HEK293, His) is the recombinant mouse-derived LDLR protein, expressed by HEK293 , with C-His labeled tag and A23V, C27G mutation. The total length of LDLR Protein, Mouse (Biotinylated, A23V, C27G, HEK293, His) is 790 a.a., with molecular weight of ~85.7 kDa.

HY-P76477

LRP-11 Protein, Human (HEK293, His)

Low-density lipoprotein receptor-related protein 11; LRP-11
Human HEK293

HY-P73835

	LOX-1/OLR1 Protein, Rat (HEK293, His) Oxidized low-density lipoprotein receptor 1; LOX-1; OLR1; CLEC8A	Rat	HEK293
	The LOX-1/OLR1 protein plays an important role as a receptor that recognizes, internalizes, and degrades oxidatively modified low-density lipoprotein (oxLDL), a marker of atherosclerosis, in vascular endothelial cells. OxLDL induces endothelial dysfunction, triggering pro-inflammatory responses, oxidative conditions, and apoptosis. LOX-1/OLR1 Protein, Rat (HEK293, His) is the recombinant rat-derived LOX-1/OLR1 protein, expressed by HEK293 , with N-His labeled tag. The total length of LOX-1/OLR1 Protein, Rat (HEK293, His) is 305 a.a., with molecular weight of 43-47 kDa.

HY-P73836

	LOX-1/OLR1 Protein, Rat (HEK293, Fc) Oxidized low-density lipoprotein receptor 1; LOX-1; OLR1; CLEC8A	Rat	HEK293
	The LOX-1/OLR1 protein plays an important role as a receptor that recognizes, internalizes, and degrades oxidatively modified low-density lipoprotein (oxLDL), a marker of atherosclerosis, in vascular endothelial cells. OxLDL induces endothelial dysfunction, triggering pro-inflammatory responses, oxidative conditions, and apoptosis. LOX-1/OLR1 Protein, Rat (HEK293, Fc) is the recombinant rat-derived LOX-1/OLR1 protein, expressed by HEK293 , with N-hFc labeled tag. The total length of LOX-1/OLR1 Protein, Rat (HEK293, Fc) is 305 a.a., with molecular weight of ~66 & 35 kDa, respectively.

HY-P76474

	LOX-1/OLR1 Protein, Cynomolgus (HEK293, His) Oxidized low-density lipoprotein receptor 1; LOX-1; OLR1; CLEC8A	Cynomolgus	HEK293
	OLR1 is a type II membrane glycoprotein belonging to C-type lectin family with a short N-terminal cytoplasmic tail and a long C-terminal extracellular domain. OLR1 binds ox-LDL, delipidated, and solubilized ox-LDL. LOX-1/OLR1 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived LOX-1/OLR1 protein, expressed by HEK293 , with N-His labeled tag. The total length of LOX-1/OLR1 Protein, Cynomolgus (HEK293, His) is 213 a.a., with molecular weight of ~37 KDa.

HY-P77057

	LDLRAD3 Protein, Human (HEK293, Fc) Low-density lipoprotein receptor class A domain-containing protein 3; LRAD3	Human	HEK293
	LDLRAD3 protein significantly affects the processing of amyloid precursor protein (APP), possibly reducing soluble APP-α (sAPP-α) and increasing the production of amyloid P3 peptide. Suggested regulation of ITCH and NEDD4 E3 ligases. LDLRAD3 Protein, Human (HEK293, Fc) is the recombinant human-derived LDLRAD3 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of LDLRAD3 Protein, Human (HEK293, Fc) is 156 a.a., with molecular weight of ~43.8 KDa.

HY-P77057A

LDLRAD3 Protein, Human (HEK293, hFc)

Low-density lipoprotein receptor class A domain-containing protein 3; LRAD3
Human HEK293

HY-P76475

	LRP-10 Protein, Human (HEK293, Fc) Low-density lipoprotein receptor-related protein 10; LRP-10; MSTP087; SP220	Human	HEK293
	The LRP-10 protein is a possible receptor that may mediate internalization and/or signaling of lipophilic molecules. It is speculated that LRP-10 can promote the uptake of lipoprotein APOE in the liver and may play a role in lipid metabolism and processes related to lipoprotein transport. LRP-10 Protein, Human (HEK293, Fc) is the recombinant human-derived LRP-10 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of LRP-10 Protein, Human (HEK293, Fc) is 440 a.a., with molecular weight of 80-90 KDa.

HY-P76476

	LRP-10 Protein, Human (HEK293, His) Low-density lipoprotein receptor-related protein 10; LRP-10; MSTP087; SP220	Human	HEK293
	The LRP-10 protein is a possible receptor that may mediate internalization and/or signaling of lipophilic molecules. It is speculated that LRP-10 can promote the uptake of lipoprotein APOE in the liver and may play a role in lipid metabolism and processes related to lipoprotein transport. LRP-10 Protein, Human (HEK293, His) is the recombinant human-derived LRP-10 protein, expressed by HEK293 , with C-His labeled tag. The total length of LRP-10 Protein, Human (HEK293, His) is 424 a.a., with molecular weight of ~55 KDa.

HY-P71180

	OLR1 Protein, Human (HEK293, His) Oxidized Low-Density lipoprotein receptor 1; Ox-LDL receptor 1; C-Type Lectin Domain Family 8 Member A; Lectin-Like Oxidized LDL receptor 1; LOX-1; Lectin-Like oxLDL receptor 1; hLOX-1; Lectin-Type Oxidized LDL receptor 1; OLR1; CLEC8A; LOX1	Human	HEK293
	OLR1 Protein, a receptor on vascular endothelial cells, plays a key role in recognizing, internalizing, and degrading oxidatively modified low-density lipoprotein (oxLDL). As a marker of atherosclerosis, oxLDL induces vascular endothelial cell activation, leading to pro-inflammatory responses, oxidative conditions, and apoptosis. OLR1's association with oxLDL activates NF-kappa-B, contributing to pro-atherogenic responses such as reduced nitric oxide release, monocyte adhesion, and apoptosis. Beyond oxLDL, it serves as a receptor for HSP70, participating in cell-mediated antigen cross-presentation and functioning as a leukocyte-adhesion molecule in inflammation. Additionally, OLR1 recognizes AGE products, activated platelets, monocytes, apoptotic cells, and bacteria. OLR1 Protein, Human (HEK293, His) is the recombinant human-derived OLR1 protein, expressed by HEK293, with C-6*His labeled tag. The total length of OLR1 Protein, Human (HEK293, His) is 213 a.a., with molecular weight of 30-35 kDa.

HY-P70946

	LRP-12 Protein, Human (HEK293, His) Low-Density lipoprotein receptor-Related Protein 12; LRP-12; Suppressor of Tumorigenicity 7 Protein; LRP12; ST7	Human	HEK293
	LRP-12, a probable receptor, potentially facilitates the internalization of lipophilic molecules and signal transduction. It may function as a tumor suppressor and interacts with proteins RACK1, ZFYVE9, and NMRK2. LRP-12 Protein, Human (HEK293, His) is the recombinant human-derived LRP-12 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of LRP-12 Protein, Human (HEK293, His) is 456 a.a., with molecular weight of ~64-85 kDa.

Cat. No.	Product Name	Chemical Structure

HY-B0144AS1

Pitavastatin-d5 sodium
Pitavastatin-d₅ (sodium) is the deuterium labeled Pitavastatin sodium. Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity.

HY-B0144S

Pitavastatin-d4 hemicalcium

Pitavastatin-d₄ (hemicalcium) is deuterium labeled Pitavastatin (Calcium). Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity[1][2][3].

Cat. No.	Product Name	Application	Reactivity

HY-P81109

LDLR Antibody LDLR_HUMAN; Low-density lipoprotein receptor; LDL receptor; FH; FHC; FHCL1; LDLCQ2; low density lipoprotein receptor	WB; ELISA; Flow-Cyt; ICC	Human, Mouse(predicted: Rat, Dog, Pig, Cow, Horse, Rabbit, Guinea Pig)
LDLR Antibody is an unconjugated, approximately 92 kDa, rabbit-derived, anti-LDLR polyclonal antibody. LDLR Antibody can be used for: WB, ELISA, Flow-Cyt, ICC expriments in human, mouse, and predicted: rat, dog, pig, cow, horse, rabbit, guinea pig background without labeling.

HY-P81172

LOX 1 Antibody Lectin-type oxidized LDL receptor 1; OLR1; lectin-like low density lipoprotein receptor-1; Oxidized low-density lipoprotein receptor 1; Ox-LDL receptor 1; Lectin-like oxidized LDL receptor 1; Lectin-like oxLDL receptor 1; LOX-1; BLOX1; Contains: Oxidized low-density lipoprotein receptor 1, soluble form A; Oxidized low-density lipoprotein receptor 1, soluble form B; OLR1_HUMAN.	WB; ELISA; IHC-P; IHC-F; IF	Human, Rat, Rabbit(predicted: Mouse, Cow)
LOX 1 Antibody is an unconjugated, approximately 31/50 kDa, rabbit-derived, anti-LOX 1 polyclonal antibody. LOX 1 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in human, rat, rabbit, and predicted: mouse, cow background without labeling.

HY-P82383

ApoER2 Antibody (YA2128)

LRP8; APOER2; Low-density lipoprotein receptor-related protein 8; LRP-8; Apolipoprotein E receptor 2
WB, IP Human, Rat, Hamster
HY-P83131

LRP2 Antibody (YA2876)

Low-density lipoprotein receptor-related protein 2; LRP-2; Glycoprotein 330; gp330; Megalin; LRP2; DBS
WB Human, Mouse, Rat

HY-P82565

SorLA Antibody (YA2310) SORL1; C11orf32; Sortilin-related receptor; Low-density lipoprotein receptor relative with 11 ligand-binding repeats; LDLR relative with 11 ligand-binding repeats; LR11; SorLA-1; Sorting protein-related receptor containing LDLR class A repe	WB, IHC-P	Human, Mouse, Rat

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks